In Vitro Activity of Manogepix against Multidrug-Resistant and Panresistant Candida auris from the New York Outbreak
Open accessPublished version of a preprint
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
An ongoing Candida auris outbreak in the New York metropolitan area is the largest recorded to date in North America. Laboratory surveillance revealed NY C. auris isolates are resistant to fluconazole, with variable resistance to other currently used broad-spectrum antifungal drugs, and that several isolates are panresistant. Thus, there is an urgent need for new drugs with a novel mechanism of action to combat the resistance challenge. Manogepix (MGX) is a first-in-class agent that targets the fungal Gwt1 enzyme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This is consistent with previous in vitro studies showing MGX to be the most potent antifungal tested against C. auris isolates (21, 22).”
From Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial (2023) · cites this paper as [21]
In the citing paper
“Another study that focused on 200 C. auris strains collected between 2017 and 2020 in New York and New Jersey reported low MICs for MGX even against pan-resistant strains shown to be resistant to the 3 main classes of antifungal drugs (i.e., azoles, polyenes, and echinocandins) (21).”
From Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial (2023) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 3×
“variable patterns of resistance to amphotericin B, azoles, and echinocandins; (3) MGX”
BackgroundResultKathuria, S., Singh, P. K., Sharma, C., Prakash, A., Masih, A., Kumar, A., Meis, J. F., & Chowdhary, A. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00367-15 · Cited by 532 · cited 1×
“The observed pattern is higher than that reported in other published studies, including South Asian clade I isolates (3, 29, 36), and also included organisms with AMB MIC values as high as 32 mg/liter.”
ResultChow, N. A., Muñoz, J. F., Gade, L., Berkow, E., Li, X., Welsh, R. M., Forsberg, K., Lockhart, S. R., Adam, R., Alanio, A., et al. (2020) · doi:10.1101/2020.01.06.896548 · Cited by 463
Arendrup, M. C., Cuenca-Estrella, M., Lass-Flörl, C., & Hope, W. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03880.x · Cited by 451
Turnidge, J., Kahlmeter, G., & Kronvall, G. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01377.x · Cited by 397 · cited 2×
“The WT-UL for MGX for MGX were estimated using the Microsoft Excel spreadsheet calculator ECOFFinder (27, 28).”
MethodInfluentialPotential Fifth Clade of Candida auris, Iran, 2018
Chow, N. A., de Groot, T., Badali, H., Abastabar, M., Chiller, T. M., & Meis, J. F. (2019) · Emerging Infectious Diseases · doi:10.3201/eid2509.190686 · Cited by 356 · cited 1×
“auris emerged independently in four regions, namely, South Asia, East Asia, Africa, and South America, defined by clades I, II, II, and IV, respectively (3), with Iranian clade V arising more recently (4).”
BackgroundVallabhaneni, S., Kallen, A., Tsay, S., Chow, N., Welsh, R., Kerins, J., Kemble, S. K., Pacilli, M., Black, S. R., Landon, E., et al. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6544e1 · Cited by 302
Self-citationCandida auris in Healthcare Facilities, New York, USA, 2013–2017
Adams, E., Quinn, M., Tsay, S., Poirot, E., Chaturvedi, S., Southwick, K., Greenko, J., Fernandez, R., Kallen, A., Vallabhaneni, S., et al. (2018) · Emerging Infectious Diseases · doi:10.3201/eid2410.180649 · Cited by 284
Self-citationArendrup, M. C., Prakash, A., Meletiadis, J., Sharma, C., & Chowdhary, A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00485-17 · Cited by 270
Vallabhaneni, S., Kallen, A., Tsay, S., Chow, N., Welsh, R., Kerins, J., Kemble, S. K., Pacilli, M., Black, S. R., Landon, E., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14121 · Cited by 247 · cited 2×
“isolates tested to date; (2) MGX MICs were unchanged against C.”
BackgroundSelf-citation
Research works printed but not linked: 2
- Hata K, Horii T, Miyazaki M, Watanabe N. 2011. In vitro and in vivo antifungal activities of E1211, a water-soluble prodrug of E1210, abstr F1-1377. Abstr Interscience Conference on Antimicrobial Agents Chemotherapy. American Society for Microbiology, Washington, DC. [Google Scholar]
- CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts Approved standard M27-A3. Vol. 28 No. 14 Clinical Laboratory Standards Institute, Wayne, PA. [Google Scholar]
Cited by
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467
Shaw, K. J., & Ibrahim, A. S. (2020) · Journal of Fungi · doi:10.3390/jof6040239 · Cited by 229
“MGX was 8- to 32-fold more active than the echinocandins, 16- to 64-fold more active than the azoles, and 64-fold more active than AMB [35].”
BackgroundInfluentialSelf-citationHoenigl, M., Arastehfar, A. A., Arendrup, M. C., Brüggemann, R. J. M., Carvalho, A., Chiller, T. M., Chen, W., Egger, M., Feys, S., Gangneux, J., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-23 · Cited by 186
Antifungal Resistance and the Role of New Therapeutic Agents
Logan, A., Wolfe, A. L., & Williamson, J. (2022) · Current Infectious Disease Reports · doi:10.1007/s11908-022-00782-5 · Cited by 117
New treatment options for critically important WHO fungal priority pathogens
Kriegl, L., Egger, M., Boyer, J., Hoenigl, M., & Krause, R. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.03.006 · Cited by 105
Vazquez, J. A., Pappas, P. G., Boffard, K., Paruk, F., Bien, P. A., Tawadrous, M., Ople, E., Wedel, P., Oborska, I., & Hodges, M. R. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01419-22 · Cited by 92
“, azoles, polyenes, and echinocandins) (21).”
Novel antifungal agents in clinical trials
Jacobs, S. E., Zagaliotis, P., & Walsh, T. J. (2021) · F1000Research · doi:10.12688/f1000research.28327.1 · Cited by 82
Pappas, P. G., Vazquez, J. A., Oren, I., Rahav, G., Aoun, M., Bulpa, P., Ben-Ami, R., Ferrer, R., Mccarty, T., Thompson, G. R., et al. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad256 · Cited by 65
Billamboz, M., Fatima, Z., Hameed, S., & Jawhara, S. (2021) · Microorganisms · doi:10.3390/microorganisms9030634 · Cited by 56
McCarty, T. P., & Pappas, P. G. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.732223 · Cited by 53
Hoenigl, M., Sprute, R., Arastehfar, A., Perfect, J. R., Lass-Flörl, C., Bellmann, R., Prattes, J., Thompson, G. R., Wiederhold, N. P., Al Obaidi, M. M., et al. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2086120 · Cited by 45
“Wild-type C. dubliniensis, C. fabianii, C. glabrata, C. inconspicua, C. kefyr, C. krusei, C. lipolytica, C. pulcherrima, C. sojae, and C. tropicalis were also inhibited by MICs ≤0.125 µg/ml [72,73].”
BackgroundInfluentialMaphanga, T. G., Mpembe, R. S., Naicker, S. D., Govender, N. P., & GERMS-SA, F. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01717-21 · Cited by 42
“It is possible that the activity of manogepix is not affected by all the mechanisms of fluconazole resistance (24).”
BackgroundAlmajid, A., Bazroon, A. A., Al-Awami, H., Albarbari, H., Alqahtani, I., Almutairi, R., Alsuwayj, A., Alahmadi, F., Aljawad, J., Alnimer, R., et al. (2024) · Cureus · doi:10.7759/cureus.59210 · Cited by 50
“The MIC values for these isolates varied from 0.008 mg/liter to 0.015 mg/liter, with a median and mode of 0.015 mg/liter [23].”
BackgroundInfluentialNovel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician
Lamoth, F. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s375625 · Cited by 43
John, L. L. H., Thomson, D. D., Bicanic, T. A., Hoenigl, M., Brown, A. J. P., Harrison, T. S., & Bignell, E. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01645-22 · Cited by 37
Kovács, R., Nagy, F., Tóth, Z., Forgács, L., Tóth, L., Váradi, G., Tóth, G. K., Vadászi, K., Borman, A. M., Majoros, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020771 · Cited by 36
“auris, including ibrexafungerp [19], manogepix [20], VT-1598 [21], and rezafungin [22] and they may represent potential treatment options in the near future.”
BackgroundUniqueness of Candida auris cell wall in morphogenesis, virulence, resistance, and immune evasion
Dakalbab, S., Hamdy, R., Holigová, P., Abuzaid, E. J., Abu-Qiyas, A., Lashine, Y., Mohammad, M. G., & Soliman, S. S. M. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127797 · Cited by 31
Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review
Treviño‐Rangel, R. D. J., González, G. M., Montoya, A. M., Rojas, O. C., Elizondo-Zertuche, M., & Álvarez‐Villalobos, N. A. (2022) · Journal of Fungi · doi:10.3390/jof8111144 · Cited by 29
Treatment of invasive candidiasis in the era of Candida resistance
Paiva, J.-A., & Pereira, J. M. (2023) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001077 · Cited by 35
Small molecules for combating multidrug-resistant superbug Candida auris infections
Tu, J., Liu, N., Huang, Y., Yang, W., & Sheng, C. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.001 · Cited by 29
Recent advances and future perspectives in the pharmacological treatment ofCandida aurisinfections
Giacobbe, D. R., Magnasco, L., Sepulcri, C., Mikulska, M., Koehler, P. A., Cornely, O. A., & Bassetti, M. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1949285 · Cited by 26
Zhang, W., Cao, X., Liu, C., & Gao, S. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1694108 · Cited by 24
Candida auris in Austria—What Is New and What Is Different
Spettel, K., Kriz, R., Wu, C. C., Achter, L., Schmid, S., Galazka, S., Selitsch, B., Camp, I., Makristathis, A., Lagler, H., et al. (2023) · Journal of Fungi · doi:10.3390/jof9020129 · Cited by 21
Lee, A., Wang, N., Carter, C. L., Zimmerman, M., Dartois, V. A., Shaw, K. J., Perlin, D. S., & Zhao, Y. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02476-20 · Cited by 21
Self-citationCurrent Perspectives of Antifungal Therapy: A Special Focus on Candida auris
Arumugam, G., Muthuselvam, M., de Lima, P. M. N., Rajendran, R., & Junqueira, J. C. (2024) · Journal of Fungi · doi:10.3390/jof10060408 · Cited by 22
“Manogepix also showed activity against clinical isolates from the New York outbreak, with MIC values of 0.008 to 0.015 mg/L against pan-resistant isolates [51].”
BackgroundInfluentialCandida auris : host interactions, antifungal drug resistance, and diagnostics
Chowdhary, A., Lionakis, M. S., & Chauhan, N. (2025) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00187-22 · Cited by 22
“Fosmanogepix also demonstrates in vitro activity against C. auris isolates that are resistant to fluconazole, echinocandins, and amphotericin B (204).”
Candida auris, a singular emergent pathogenic yeast: its resistance and new therapeutic alternatives
Fernandes, L., Ribeiro, R., Henriques, M., & Rodrigues, M. E. (2022) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-022-04497-2 · Cited by 17
de Moraes, D. C. (2021) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2021.101232 · Cited by 17
Hirayama, T., Miyazaki, T., Tanaka, R., Kitahori, N., Yoshida, M., Takeda, K., Ide, S., Iwanaga, N., Tashiro, M., Takazono, T., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01508-24 · Cited by 15
“Although manogepix showed excellent in vitro activity against C. auris clinical isolates (27, 28), it is important to note that fluconazole resistant strains with elevated CDR1 expression may be less susceptible to manogepix.”
Broad susceptibility of Candida auris strains to 8-hydroxyquinolines and mechanisms of resistance
Lohse, M. B., Laurie, M. T., Levan, S., Ziv, N., Ennis, C. L., Nobile, C. J., DeRisi, J. L., & Johnson, A. D. (2023) · mBio · doi:10.1128/mbio.01376-23 · Cited by 16
Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix
August, B., & Kale-Pradhan, P. B. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2926 · Cited by 11
Siopi, M., Leventaki, S., Pachoulis, I., Spruijtenburg, B., Meis, J. F. G. M., Pournaras, S., Vrioni, G., Tsakris, A., & Meletiadis, J. (2025) · Journal of Clinical Microbiology · doi:10.1128/jcm.00399-25 · Cited by 10
“The corresponding results obtained for strains isolated in the USA ( n = 200) (35) and Kuwait ( n = 314) (36) were more pronounced, as the resistance rates according to Etest-generated susceptibility data were 46% (modal MIC and MIC 90 values of 1 and 2 mg/L, respectively) and 64% (modal MIC and…”
Candida auris in intensive care unit: A growing clinical concern
Bassetti, M., Magnasco, L., Lamarina, A., Paola, L. D., Vena, A., Giacobbe, D. R., & Bartalucci, C. (2025) · Journal of Translational Critical Care Medicine · doi:10.1097/jtccm-d-25-00003 · Cited by 10
New Perspectives on Antimicrobial Agents: Fosmanogepix
Lamoth, F. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00324-26 · Cited by 6
“Notably, constantly low MICs (≤0.06 µg/mL) were observed among C. auris isolates (32–34).”
InfluentialInfection caused by Candida auris: state of the art
Marena, G. D., Carvalho, G. C., Monazzi, L., Maschio-Lima, T., Almeida, M. D., Silva, J. D., Fortunato, G., Araújo, V., Venancio, D. C. V., Chang, M., et al. (2022) · Mycosphere · doi:10.5943/mycosphere/13/1/10 · Cited by 6
New Antifungal Drugs: Discovery and Therapeutic Potential
Vicente, F., Reyes, F., & Genilloud, O. (2024) · Springer eBooks · doi:10.1007/978-981-99-5696-8_12 · Cited by 6
Almeida‐Silva, F., Marques, F. P. N., Tenório-Alvarenga, P. H., Poester, V. R., Xavier, M. O., Zancopé‐Oliveira, R. M., & Almeida‐Paes, R. (2025) · Brazilian Journal of Microbiology · doi:10.1007/s42770-025-01711-z · Cited by 3
AlBahrani, S. (2025) · Microbiology Research · doi:10.3390/microbiolres16100221 · Cited by 4
“Ultraviolet-C (UV-C) Systems : Ultraviolet-C (UV-C) disinfection systems, which emit light within the germicidal spectrum of 200–280 nm, function by inducing photodimerisa-tion of DNA and RNA, thereby disrupting the genomic integrity of microorganisms and halting their replication [52].”
The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis
Zubovskaia, A., & Vázquez, J. A. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s547511 · Cited by 3
“99 Moreover, fosmanogepix in combination with anidulafungin demonstrated synergistic activity against C. auris isolates in vitro.”
Ramos, L. S., Silva, L. N., de Mello, T. P., Frota, H. F., Branquinha, M. H., & dos Santos, A. L. S. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220520153748 · Cited by 3
de Jong, A. W., Boden, S., Zandijk, A., Kortsinoglou, A. M., van den Ende, B. G., Francisco, E. C., Nefeli, P. K., Kouvelis, V. N., Zhou, M., & Hagen, F. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.16.594571 · Cited by 4
Shao, F., Wu, T., & Su, J. (2026) · Mycopathologia · doi:10.1007/s11046-026-01111-3 · Cited by 1
“Automated microfluidic platforms further streamline point-of-care testing, delivering results in 3–4 h for critical care triage, pending future cost optimizations [14].”
Negi, P., Verma, N., Rishi, P., Multani, K., Sharma, M., Kumari, S., & Raj, K. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-04864-z · Cited by 1
Morelo, M. J., Firacative, C., García‐Effrón, G., Gómez, B. L., & Ceballos-Garzón, A. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.107870 · Cited by 1
Candida , Cryptococcus , and Other Yeasts of Medical Importance
Borman, A. M., & Johnson, E. M. (2023) · Wiley eBooks · doi:10.1002/9781683670438.mcm0121 · Cited by 2
Candida , Cryptococcus , and Other Yeasts of Medical Importance
Borman, A. M., & Johnson, E. M. (2023) · Wiley eBooks · doi:10.1002/9781683674849.mcm0121 · Cited by 1
Kopczyk, M. K., Mulroney, K. T., Weaire‐Buchanan, G., Paton, T. F., Salisbury, E., Ho, W. S., Gardam, D. J., Higgins, A., Carson, C. F., Inglis, T. J. J., et al. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1813126
“…in Japan in 2009 (Satoh et al., 2009), C. auris has spread in hospitals in Europe, the US, India, Pakistan and South Africa (Politi et al., 2024; Zhu et al., 2020; Ashraf et al., 2023; Farooqi et al., 2020; Shuping et al., 2023) with approximately 90% of isolates resistant to the most widely…”
Hameed, T., John, L. L. H., Bignell, E., & Tanaka, R. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.19.733372
Hirayama, T., Kitahori, N., Ishimine, M., Nakada, N., Ito, Y., Iwanaga, N., Takazono, T., Miyazaki, T., Izumikawa, K., Yanagihara, K., et al. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.02078-26
Zhu, G., Zheng, N., Zhai, P., & Mou, Y. (2026) · Biomedical Reports · doi:10.3892/br.2026.2204
“Potent activity is also maintained against multidrug‑resistant and pan‑resistant C. auris strains isolated during the New York outbreak (59,60).”
Metadata
- Authors
- Zhu, Y., Kilburn, S., Kapoor, M., Chaturvedi, S., Shaw, K. J., & Chaturvedi, V.
- Affiliations
- New York State Department of Health (US)
- Amplyx Pharmaceuticals (United States) (US)
- Hearts Consulting Group, Poway, California, USA
- Corresponding author
- Shaw, Karen Joy
- Chaturvedi, Vishnu
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2020-10-20
- Volume
- 64
- Issue
- 11
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC7577132
- OpenAlex
- W3080618403
- Cited by
- 50
- References
- 41
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 9 · 2023: 10 · 2022: 8 · 2021: 8 · 2020: 1
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amplyx Pharmaceuticals
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- manogepix, Candida auris, multidrug resistance, panresistance, fluconazole resistance, antifungal resistance, in vitro antifungal activity
- MeSH terms
- Aminopyridines, Antifungal Agents, Candida, Disease Outbreaks, Isoxazoles, Microbial Sensitivity Tests, New York, North America
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.